Savara (SVRA) Net Cash Flow (2010 - 2026)
Savara (SVRA) posted quarterly Net Cash Flow of $5.5 million for Q1 2026, up 24.2% year-over-year from $4.5 million in Q1 2025, and down 67.31% quarter-over-quarter from $16.9 million in Q4 2025.
Savara (SVRA) Net Cash Flow (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Net Cash Flow for 17 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 24.2% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $19.4 million (up 591.17% YoY), while the FY2025 annual figure was $18.3 million, up 260.05% from the prior year.
- Net Cash Flow slipped to $5.5 million in Q1 2026 per SVRA's latest filing, from $16.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $45.2 million in Q1 2022 and bottomed at -$67.9 million in Q4 2022.
- Historically, Net Cash Flow has averaged $305588.2 across 5 years, with a median of -$1.1 million in 2025.
- On a YoY basis, Net Cash Flow climbed as much as 510.75% in 2022 and fell as far as 538.69% in 2022.
- Savara's Net Cash Flow stood at -$67.9 million in 2022, then surged by 98.32% to -$1.1 million in 2023, then sank by 447.85% to -$6.2 million in 2024, then surged by 371.94% to $16.9 million in 2025, then tumbled by 67.31% to $5.5 million in 2026.
- Business Quant data shows SVRA's Net Cash Flow at $5.5 million in Q1 2026, $16.9 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.03 Mn |
| Jun 30, 2026 | 3.03 Mn |
| Mar 31, 2026 | 5.54 Mn |
| Mar 31, 2026 | 5.54 Mn |
| Dec 31, 2025 | 16.94 Mn |
| Dec 31, 2025 | 16.94 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -1.98 Mn |
| Jun 30, 2025 | -1.98 Mn |
| Mar 31, 2025 | 4.46 Mn |
| Mar 31, 2025 | 4.46 Mn |
| Dec 31, 2024 | -6.23 Mn |
| Dec 31, 2024 | -6.23 Mn |
| Sep 30, 2024 | -2.52 Mn |
| Sep 30, 2024 | -2.52 Mn |
| Jun 30, 2024 | 7.10 Mn |
| Jun 30, 2024 | 7.10 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Mar 31, 2024 | -9.80 Mn |